Related Experiment Videos
Biomarkers in inflammatory bowel disease
Simon W Beaven1, Maria T Abreu
1Basic and Translational Research, Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Current Opinion in Gastroenterology
|February 11, 2005
Summary
Biomarkers aid in distinguishing inflammatory bowel diseases (IBD) like Crohn disease and ulcerative colitis. These markers help predict disease progression and stratify patients for tailored therapy, improving treatment outcomes.
Area of Science:
- Gastroenterology
- Immunology
- Biomarker Discovery
Background:
- Inflammatory bowel disease (IBD) encompasses Crohn disease and ulcerative colitis, characterized by chronic intestinal inflammation.
- The diverse clinical presentations suggest varied underlying pathogenetic mechanisms.
- Identifying reliable biomarkers is crucial for accurate diagnosis and management.
Purpose of the Study:
- To review current information on biomarkers for Crohn disease and ulcerative colitis.
- To highlight the role of biomarkers in predicting disease course and therapeutic response.
Main Methods:
- Focus on serologic, genetic, and biochemical markers.
- Review of emerging data supporting biomarker utility.
- Consideration of future applications of functional genomics and proteomics.
Main Results:
- Serologic markers (e.g., perinuclear antineutrophil cytoplasmic antibody, anti-Saccharomyces cerevisiae antibody) assist in differentiating IBD subtypes and predicting complications.
- Genetic markers (e.g., CARD15/NOD2) show future potential for predicting disease course.
- Biochemical markers (e.g., C-reactive protein) are valuable for stratifying patients for biologic therapies and monitoring treatment response.
Conclusions:
- Biomarkers enable stratification of IBD patients into homogeneous subgroups.
- This stratification aids in predicting therapy response and disease progression.
- Future advancements in omics technologies will enhance personalized IBD management.